Co-administration reduces divalproex sodium concentrations below therapeutic range, increasing risk of breakthrough seizures. Use is generally not recommended.
Source: NLP:meropenem
Meropenem Interactions
Brand names: Meropenem
Penem Antibacterial
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS Meropenem for injection is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta(β)-lactams. Known hypersensitivity to product components or anaphylactic reactions to β-lactams. (4)
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are insufficient human data to establish whether there is a drug-associated risk of major birth defects or miscarriages with meropenem in pregnant women. No fetal toxicity or malformations were observed in pregnant rats and Cynomolgus monkeys administered intravenous meropenem during organogenesis at doses up to 2.4 and 2.3 times the maximum recommended human dose (MRHD) based on body surface area comparison, respectively. In rats administered intravenous meropenem in late pregnancy and during the lactation period, there were no adverse effects on offspring at doses equivalent to approximately 3.2 times the MRHD based on body surface area comparison ( see Data ). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Meropenem administered to pregnant rats during organogenesis (Gestation Day 6 to Gestation Day 17) in intravenous doses of 240, 500, and 750 mg/kg/day was associated with mild maternal weight loss at all doses, but did not produce malformations or fetal toxicity. The no-observed-adverse-effect-level (NOAEL) for fetal toxicity in this study was considered to be the high dose of 750 mg/kg/day (equivalent to approximately 2.4 times the MRHD of 1 gram every 8 hours based on body surface area comparison). Meropenem administered intravenously to pregnant Cynomolgus monkeys during organogenesis from Day 20 to 50 after mating at doses of 120, 240, and 360 mg/kg/day did not produce maternal or fetal toxicity at the NOAEL dose of 360 mg/kg/day (approximately 2.3 times the MRHD based on body surface area comparison). In a peri-postnatal study in rats described in the published literature2, intravenous meropenem was adm
5 interactions on record
Clinically significant reduction in serum valproic acid concentration reported, potentially resulting in loss of seizure control.
Source: NLP:divalproex sodium er
Carbapenem antibiotic causing clinically significant reduction in serum valproic acid concentration, potentially resulting in loss of seizure control.
Source: NLP:divalproex sodium d/r
Probenecid inhibits renal excretion of meropenem, resulting in increased plasma concentrations. Co-administration is not recommended.
Source: NLP:meropenem
Co-administration reduces valproic acid concentrations below therapeutic range, increasing risk of breakthrough seizures. Use is generally not recommended.
Source: NLP:meropenem